[Lipid-Lowering Therapy for Patients with Dyslipidemia].

Q4 Medicine
Chiaki Yokota
{"title":"[Lipid-Lowering Therapy for Patients with Dyslipidemia].","authors":"Chiaki Yokota","doi":"10.11477/mf.1436205032","DOIUrl":null,"url":null,"abstract":"<p><p>In patients without cardiovascular disease(primary prevention), the diagnosis of dyslipidemia is the initial step in lipid management. The 2022 guidelines for atherosclerotic disease prevention provide a validated clinical scoring tool to estimate the 10-year risk of atherosclerotic disease derived from the Hisayama study. For primary prevention, patients are classified into the categories of low(<2%), intermediate(2 to<10%)and high(≧10%)risk. Patients with diabetes mellitus, chronic kidney disease, or peripheral arterial disease are considered at high risk without calculating the risk score. Lifestyle intervention is initiated, followed by low-density lipoprotein cholesterol(LDL-C)-lowering therapy with statins aimed at the target levels. Secondary prevention of acute coronary syndrome, diabetes mellitus, and atherosclerotic brain infarction is associated with the highest risk of cardiovascular disease. High-intensity statin therapy is recommended as the first-line treatment in this group to achieve less than 70 mg/dL of LDL-C levels. The addition of ezetimibe is recommended first if LDL-C levels remain elevated with maximal statins. The addition of a Proprotein Convertase Subtilisin/Kexin type 9 inhibitor to strong statins is recommended for patients with coronary artery disease whose LDL-C levels remain elevated despite the administration of maximal LDL-C-lowering therapy. Secondary dyslipidemia should be managed using causative diseases or drugs. Patients with familial hypercholesterolemia should be referred to specialists.</p>","PeriodicalId":35984,"journal":{"name":"Neurological Surgery","volume":"52 6","pages":"1155-1166"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.1436205032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In patients without cardiovascular disease(primary prevention), the diagnosis of dyslipidemia is the initial step in lipid management. The 2022 guidelines for atherosclerotic disease prevention provide a validated clinical scoring tool to estimate the 10-year risk of atherosclerotic disease derived from the Hisayama study. For primary prevention, patients are classified into the categories of low(<2%), intermediate(2 to<10%)and high(≧10%)risk. Patients with diabetes mellitus, chronic kidney disease, or peripheral arterial disease are considered at high risk without calculating the risk score. Lifestyle intervention is initiated, followed by low-density lipoprotein cholesterol(LDL-C)-lowering therapy with statins aimed at the target levels. Secondary prevention of acute coronary syndrome, diabetes mellitus, and atherosclerotic brain infarction is associated with the highest risk of cardiovascular disease. High-intensity statin therapy is recommended as the first-line treatment in this group to achieve less than 70 mg/dL of LDL-C levels. The addition of ezetimibe is recommended first if LDL-C levels remain elevated with maximal statins. The addition of a Proprotein Convertase Subtilisin/Kexin type 9 inhibitor to strong statins is recommended for patients with coronary artery disease whose LDL-C levels remain elevated despite the administration of maximal LDL-C-lowering therapy. Secondary dyslipidemia should be managed using causative diseases or drugs. Patients with familial hypercholesterolemia should be referred to specialists.

[血脂异常患者的降脂治疗]。
对于无心血管疾病(一级预防)的患者,诊断血脂异常是脂质管理的第一步。2022年动脉粥样硬化性疾病预防指南提供了一种有效的临床评分工具,用于评估Hisayama研究得出的动脉粥样硬化性疾病的10年风险。在一级预防方面,病人被分为低(
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neurological Surgery
Neurological Surgery Medicine-Medicine (all)
自引率
0.00%
发文量
99
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信